title: Blockade of cocaine-induced conditioned place preference: relevance to cocaine abuse therapeutics.
abstract: Conditioned place preference/aversion testing is a behavioral method believed capable of measuring the affective (positive, neutral or negative) properties of psychoactive drugs. Cocaine injections in rats reliably produces a positive place preference. Drugs that attenuate or block this effect of cocaine have obvious potential for developing treatments to address cocaine addiction as well as to add to the scientific understanding of the mechanism of cocaine's action at the cellular level. To date, six drugs have been reported to block the expression of a cocaine-induced conditioned place preference (CPP) and this review evidences the cocaine-induced CPP blockage by the two potent L-type calcium channel blockers, isradipine and nifedipine, the two serotonin-3 receptor antagonists, MDL72222 and ICS205-930, the delta opioid receptor selective antagonist naltrindole, and lastly, a mixed opioid agonist-antagonist buprenorphine. Additional evidence relating to the blockade of other cocaine behavioral effects by these putative blockers is addressed, where appropriate, from studies employing other procedures such as drug stimulus discrimination, self-administration, electrical brain stimulation and increases in locomotor activity. The significance of these findings is discussed in the context of their relevance to the development of treatment regimens to allow for cessation of cocaine abuse.
authors.affiliation: Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272-0095.
authors.forename: D J
authors.initials: DJ
authors.lastname: Calcagnetti
authors.forename: B J
authors.initials: BJ
authors.lastname: Keck
authors.forename: L A
authors.initials: LA
authors.lastname: Quatrella
authors.forename: M D
authors.initials: MD
authors.lastname: Schechter
mesh_terms: D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D003042:Cocaine / Q000037:antagonists & inhibitors*; D003213:Conditioning, Psychological / Q000187:drug effects*; D006801:Humans; D009292:Narcotic Antagonists / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D019966:Substance-Related Disorders / Q000188:drug therapy*
chemical_list: D002121:Calcium Channel Blockers; D009292:Narcotic Antagonists; D012702:Serotonin Antagonists; D003042:Cocaine